141 results on '"Le Tourneau C"'
Search Results
2. 186P Post-anti-PD1 tumor characterization of HPV-negative R/M SCCHN: An EORTC IMMUcan sub-project
3. PCR132 Correlation Between Quality of Life (QoL) of Patients Treated With Nivolumab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (R/M SCCHN) and Their Caregivers
4. 21P Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE)
5. Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
6. Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens
7. Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
8. 5MO Hypomethylation of circulating retrotransposons: Towards a non-invasive pan-cancer diagnosis
9. Essais précoces pour les patients porteurs de corticosurrénalomes avancés : étude rétrospective au sein du réseau endocan-comete
10. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors
11. 703TiP A randomised, double-blind, placebo-controlled phase II study of setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (rmSCCHN)
12. 705TiP Phase II trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti-TIM-3) as first-line treatment in patients with PD-L1-positive recurrent/metastatic squamous cell carcinoma of the head and neck
13. 489P Analysis of 3-dimensional volumetric distribution and dispersion of the radioenhancer NBTXR3 in various solid malignancies
14. 658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040
15. 695P Effectiveness and quality-of-life (QoL) data from real-world study (ProNiHN) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with nivolumab (nivo) in France
16. LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study
17. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
18. 173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2
19. Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients
20. Assessing the impact of organ-specific lesion dynamics on survival in patients with recurrent urothelial carcinoma treated with atezolizumab or chemotherapy
21. A phase I dose expansion study of NBTXR3, radiation enhancing hafnium oxide nanoparticles, for the treatment of cisplatin-ineligible locally advanced HNSCC patients
22. Phase I Study of Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients
23. 75P Tumor mutational burden in clinical routine practice: Identifying the right threshold?
24. 923P Nivolumab in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN) progressing on/or after a platinum-based therapy: Interim analysis of a prospective French real-world study (ProNiHN)
25. 896P Long-responders to ICI in R/M-HNSCC: A retrospective multicentric French cohort
26. PO-0992 Outcomes and toxicities of curative reirradiation for head and neck carcinomas
27. Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery
28. OC-0515 NBTXR3 activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients
29. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial
30. Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications
31. 63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies
32. Review of clinical applications of radiation-enhancing nanoparticles
33. OC-0560: RT-activated hafnium oxide nanoparticles in cisplatin-ineligible locally advanced HNSCC patients
34. NBTXR3 Radiation Enhancing Hafnium Oxide Nanoparticles Activated By Radiotherapy In Cisplatin-Ineligible Patients With Locally Advanced HNSCC: A Phase I Trial
35. 69TiP A pilot study of combined biomarker-based treatment strategies in patients with recurrent/metastatic squamous cell carcinoma of the cervix: RAIDS molecular targets trial for cervical cancer
36. 920P Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Results from a phase Ib cohort
37. LBA39 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck
38. 917MO TOPNIVO - A safety study of nivolumab in patients with recurrent and/or metastatic platinum-refractory squamous cell carcinoma of head and neck (R/M SCCHN): Final analysis
39. 970P MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with docetaxel, cisplatin and 5-FU (DCF) as induction therapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
40. 975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma
41. Hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy for the treatment of frail and/or elderly patients with locally advanced HNSCC: a phase I/II study
42. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
43. 1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 expansion cohorts in head and neck squamous cell carcinoma (HNSCC)
44. CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database
45. Medical Oncology Workload in Europe: One Continent, Several Worlds
46. Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
47. Detection of PIK3CA mutation by circulating DNA during chemotherapy: A tool to identify hard-to-treat metastatic breast cancers
48. ACCESS TO EARLY CLINICAL TRIALS IN OLDER PATIENTS IN FRANCE: AN ANALYSIS OF THE EGALICAN 2 STUDY
49. PHASE I STUDY OF HAFNIUM OXIDE NANOPARTICLES ACTIVATED BY INTENSITY MODULATED RADIATION THERAPY (IMRT) AS A NEW THERAPEUTIC OPTION FOR ELDERLY OR FRAIL HNSCC PATIENTS
50. Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.